ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on Twitter

Kidney Week

Abstract: PO1751

Prevalence of Inflammation and Associated Healthcare Resource Utilization in Patients with CKD

Session Information

Category: Health Maintenance, Nutrition, and Metabolism

  • 1300 Health Maintenance, Nutrition, and Metabolism

Authors

  • Lai, Rachel, FibroGen Inc, San Francisco, California, United States
  • Szczech, Lynda, FibroGen Inc, San Francisco, California, United States
  • Clayton, Sarah, Adelphi Group Ltd, Bollington, Cheshire East, United Kingdom
  • Harrison, Lewis, Adelphi Group Ltd, Bollington, Cheshire East, United Kingdom
  • Lowe, Mollie, Adelphi Group Ltd, Bollington, Cheshire East, United Kingdom
  • Jackson, James, Adelphi Group Ltd, Bollington, Cheshire East, United Kingdom
Background

Many patients with chronic kidney disease (CKD) suffer from inflammation, which often increases as CKD progresses. Inflammation is a risk factor for comorbidities and complicates the treatment of anemia, which is common in CKD. Inflammation has been associated with reduced red blood cell and erythropoietin production, as well as increased hepcidin levels, which can lead to functional iron deficiency. Because data on the impact of inflammation on healthcare utilization (HCRU) in patients with CKD are limited, we aimed to assess HCRU in these patients.

Methods

Data were drawn from the Adelphi CKD Disease Specific Programme™, a point-in-time survey of physicians and their patients with CKD (stage 3-5D) collected in the United States in 2018. Physician and patient reported HCRU-related information, such as the number of healthcare visits, hospitalizations, and tests conducted to diagnose and monitor patients. Inflammation was defined as C-reactive protein ≥4.9 mg/L, ferritin ≥700 ng/mL, or albumin ≤3.6 g/L. Fisher’s exact and t-tests were conducted to assess differences in HCRU between patients with and without inflammation.

Results

There were 227/703 (32%) patients with inflammation; inflammation was present in 136/491 (28%) non-dialysis-dependent, and 91/212 (43%) dialysis-dependent patients. HCRU, including the mean number of healthcare visits, tests conducted, and hospitalizations in the last 12 months, number of pills and injections taken per day, and incidences of requiring a carer were greater in patients with inflammation vs those without (all p<0.05; Table 1).

Conclusion

We found that inflammation was common in patients with CKD and associated with greater HCRU across multiple measures in a real-world setting. Novel treatment approaches in CKD that are effective in patients with inflammation may help to reduce HCRU.

Funding

  • Commercial Support